



Corrigendum: COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis

Zewen Chu^{1†}, Xin Shi^{2†}, Gaoyang Chen², Xuejun He², Yayun Qian¹, Haibo Wang¹, Li Tao³, Yanqing Liu¹, Wei Jiang^{3*} and Jue Chen^{1,2*}

¹Institution of Integrated Traditional Chinese and Western Medicine, Medical College, Yangzhou University, Yangzhou, China, ²Department of Oncology, The Second People's Hospital of Taizhou Affiliated to Medical College of Yangzhou University, Yangzhou, China, ³College of Environmental Science and Engineering, Marine Science and Technology Institute, Yangzhou University, Yangzhou, China

OPEN ACCESS

Edited and reviewed by:
Luca Rastrelli,
University of Salerno, Italy

***Correspondence:**
Wei Jiang
weijiang@yzu.edu.cn
Jue Chen
1019924551@qq.com

[†]These authors have contributed
equally to this work

Specialty section:
This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 09 December 2021
Accepted: 14 December 2021
Published: 05 January 2022

Citation:
Chu Z, Shi X, Chen G, He X, Qian Y,
Wang H, Tao L, Liu Y, Jiang W and
Chen J (2022) Corrigendum: COE
Inhibits Vasculogenic Mimicry by
Targeting EphA2 in Hepatocellular
Carcinoma, a Research Based on
Proteomics Analysis.
Front. Pharmacol. 12:831941.
doi: 10.3389/fphar.2021.831941

Keywords: vasculogenesis mimicry, hepatocellular carcinoma, EphA2, proteomics, cancer treatment

A Corrigendum on

COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis


by Chu, Z., Shi, X., Chen, G., He, X., Qian, Y., Wang, H., Tao, L., Liu, Y., Jiang, W., and Chen, J. (2021). *Front. Pharmacol.* 12:619732. doi:10.3389/fphar.2021.619732


In the original article, there was a mistake in **Figure 2**, **Figure 4**, and **Figure 6** as published. The mistake was induced by using PPT software to import all experimental pictures of each group of drugs at one time during picture sorting. In the subsequent ranking of representative pictures, the pictures of individual concentrations were mixed with those of other concentrations. The corrected **Figure 2**, **Figure 4**, and **Figure 6** appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chu, Shi, Chen, He, Qian, Wang, Tao, Liu, Jiang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.








FIGURE 6 | COE inhibits invasion and VM associated protein biomarkers via inhibiting EphA2 in HCC cells. **(A)**, COE decreases HepG2 and MHCC97-H cell invasion. Left: representative image for transwell assay, right: histogram of invaded cells. $\times 200$, 20 μm . **(B)**, COE and NVP inhibit VM formation of HepG2 and MHCC97-H on matrigel. HUVECs used as the control. **(C)**, Western blot analysis on the change of expression of VM related proteins after COE treatment.